Keros Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Der Umsatz und der Gewinn von Keros Therapeutics werden voraussichtlich um 23.2% bzw. 35.4% pro Jahr zurückgehen, während der Gewinn je Aktie voraussichtlich um 34% pro Jahr sinken wird.

Wichtige Informationen

-35.4%

Wachstumsrate der Gewinne

-34.05%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	22.7%
Wachstumsrate der Einnahmen	-23.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	05 Jan 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Nov 18

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

Aug 21

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

May 29

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

May 14

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

May 09

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Aug 07

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Jun 10

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Apr 23

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Sep 24

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Jun 10

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Dec 25

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:KROS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	56	-150	-131	N/A	9
12/31/2027	15	-171	-135	N/A	9
12/31/2026	13	-146	-127	N/A	10
12/31/2025	246	82	82	N/A	10
9/30/2025	247	64	87	89	N/A
6/30/2025	233	19	53	55	N/A
3/31/2025	215	4	43	45	N/A
12/31/2024	4	-187	-163	-161	N/A
9/30/2024	1	-182	-143	-140	N/A
6/30/2024	0	-168	-146	-144	N/A
3/31/2024	0	-160	-137	-135	N/A
12/31/2023	0	-153	-127	-125	N/A
9/30/2023	0	-142	-123	-120	N/A
6/30/2023	N/A	-127	-113	-111	N/A
3/31/2023	N/A	-116	-105	-103	N/A
12/31/2022	N/A	-105	-71	-70	N/A
9/30/2022	20	-82	-69	-68	N/A
6/30/2022	20	-79	-59	-58	N/A
3/31/2022	20	-67	-54	-53	N/A
12/31/2021	20	-59	-63	-62	N/A
9/30/2021	0	-61	-51	-51	N/A
6/30/2021	0	-53	-48	-47	N/A
3/31/2021	N/A	-49	-40	-39	N/A
12/31/2020	N/A	-45	-37	-37	N/A
9/30/2020	3	-39	-35	-34	N/A
6/30/2020	5	-31	-27	-26	N/A
3/31/2020	8	-23	-22	-22	N/A
12/31/2019	10	-14	-16	-16	N/A
12/31/2018	10	-2	N/A	7	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KROSFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-35.4% pro Jahr).

Ertrag vs. Markt: KROSFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-35.4% pro Jahr).

Hohe Wachstumserträge: KROSFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: KROSDie Einnahmen des Unternehmens werden in den nächsten 3 Jahren voraussichtlich zurückgehen (-23.2% pro Jahr).

Hohe Wachstumseinnahmen: KROSDie Einnahmen des Unternehmens werden in den nächsten drei Jahren voraussichtlich zurückgehen (-23.2% pro Jahr).

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KROS in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/01/25 17:38
Aktienkurs zum Tagesende	2026/01/23 00:00
Gewinne	2025/09/30
Jährliche Einnahmen	2024/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Keros Therapeutics, Inc. wird von 18 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Jason Zemansky	BofA Global Research
Corinne Johnson	Goldman Sachs
Andrew Fein	H.C. Wainwright & Co.

Keros Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.1% to US$88.11

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Consensus EPS estimates fall by 18%

Price target increased to US$98.75

Price target increased to US$94.00

Recent updates

Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26%

Keros Therapeutics, Inc. (NasdaqGM:KROS) announces an Equity Buyback for 10,950,165 shares, representing 35.94% for $194.37 million.

Keros Therapeutics, Inc. Announces Board and Committee Changes, Effective October 15, 2025

Keros Therapeutics, Inc. Presents Additional Clinical Data from Its Ker-065 Program At the American Society of Bone and Mineral Research 2025 Annual Meeting

Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path

ADAR1 Sends Open Letter to Keros Board of Directors

Keros Therapeutics, Inc. Announces Management Changes, Effective August 18, 2025

Keros Therapeutics, Inc. Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Growth Index

Shareholders Will Probably Hold Off On Increasing Keros Therapeutics, Inc.'s (NASDAQ:KROS) CEO Compensation For The Time Being

Keros Therapeutics, Inc. Announces Corporate Restructuring

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified

ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders

Keros Therapeutics, Inc., Annual General Meeting, Jun 04, 2025

Keros Therapeutics, Inc. Announces Initial Topline Results from the Phase 1 Clinical Trial of KER-065 in Healthy Volunteers

Keros Therapeutics: Losing Its Lead Drug Is Bad Medicine

Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial

Keros Therapeutics: How To Respond To Today's Major Safety Setback And Selloff

Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Announces Update on Enrollment in the Phase 2 Tropos Trial

Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation

Keros Therapeutics, Inc. Presents Clinical Data from its Elritercept (Ker-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association

Keros Therapeutics, Inc. Announces Leadership Updates

Keros Therapeutics: Potential Beyond KER-050 For Targeting Of Blood Cancers

Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors, Effective June 1, 2024

Are Investors Undervaluing Keros Therapeutics, Inc. (NASDAQ:KROS) By 41%?

Keros Therapeutics, Inc., Annual General Meeting, May 30, 2024

Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes

Price target increased by 7.1% to US$88.11

New major risk - Revenue and earnings growth

Chief Financial Officer notifies of intention to sell stock

Keros Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $140 million.

Insufficient new directors

Price target decreased by 9.3% to US$81.89

Consensus forecasts updated

Keros Therapeutics, Inc. Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition

Keros Therapeutics, Inc. Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Keros Therapeutics, Inc.(NasdaqGM:KROS) dropped from Russell Small Cap Comp Value Index

Chief Financial Officer notifies of intention to sell stock

We Think Keros Therapeutics (NASDAQ:KROS) Can Afford To Drive Business Growth

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its KER-050 Program and Preclinical Data from Its Alk2 Inhibitor Program At the 28Th Annual Congress of the European Hematology Association

Consensus EPS estimates fall by 18%

Insufficient new directors

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc. Presents Clinical Data from Its KER-050 and KER-047 Programs and Preclinical Data from Its KER-050 and ALK2 Inhibitor Programs At the 64Th American Society of Hematology Annual Meeting and Exposition(Continued)

Keros Therapeutics, Inc. Announces Results from A Preclinical Study of A Research Form of KER-012

Price target increased to US$98.75

Keros Therapeutics, Inc. Presents Additional Clinical Data from its KER-012 Program and Preclinical Data from its KER-050 Program at the American Society of Bone and Mineral Research 2022 Annual Meeting

Price target increased to US$94.00

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Chief Scientific Officer exercised options and sold US$57k worth of stock

Keros Therapeutics Presents Results from A Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension At the Pulmonary Hypertension Association International Conference and Scientific Sessions

Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from Its Ker-050 Program and Preclinical Data from Its Alk2 Inhibitor Program at the 27Th Annual Congress of the European Hematology Association

Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers

Price target increased to US$93.75

Keros Therapeutics Presents Results from Preclinical Study of RKER-012 in Pulmonary Arterial Hypertension at the American Thoracic Society International Conference

Chief Scientific Officer exercised options and sold US$220k worth of stock

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Chief Scientific Officer exercised options and sold US$475k worth of stock

Chief Scientific Officer exercised options and sold US$141k worth of stock

Chief Scientific Officer exercised options and sold US$137k worth of stock

Keros Therapeutics, Inc. Appoints Christopher Rovaldi as Chief Operating Officer

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely